1065 East Hillsdale Boulevard
Suite 100
Foster City, CA 94404
United States
650 525 5535
https://www.ternspharma.com
Settore/i: Healthcare
Settore: Biotechnology
Impiegati a tempo pieno: 66
Nome | Titolo | Retribuzione | Esercitate | Anno di nascita |
---|---|---|---|---|
Dr. Erin Quirk M.D. | President & Head of Research & Development | 1,06M | N/D | 1971 |
Dr. Mark Joseph Vignola Ph.D. | CFO & Treasurer | 974,16k | N/D | 1978 |
Mr. Seokho Yoon Esq. | COO, General Counsel & Secretary | 921,05k | N/D | 1978 |
Ms. Amy L. Burroughs M.B.A. | CEO & Director | N/D | N/D | 1971 |
Dr. Jeffrey R. Jasper Ph.D. | Senior VP & Head of Research | N/D | N/D | N/D |
Dr. Emil T. Kuriakose M.D. | Chief Medical Officer | N/D | N/D | 1980 |
Ms. Melita Sun Jung | Chief Business Officer | N/D | N/D | 1977 |
Terns Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, develops small-molecule product candidates for the treatment of oncology, metabolic dysfunction-associated steatohepatitis (MASH), and obesity. The company develops TERN-701, an allosteric BCR-ABL tyrosine kinase inhibitor (TKI) that is in phase 1 clinical trial for chronic myeloid leukemia (CML), a form of cancer that starts in bone marrow. It also develops TERN-501, a thyroid hormone receptor beta agonist with enhanced liver distribution and metabolic stability that is in Phase IIa clinical trial for the treatment of MASH; and TERN-601, a small-molecule Glucagon-Like Peptide-1 receptor agonist program that is intended to orally be administered for obesity. The company was incorporated in 2016 and is headquartered in Foster City, California.
L'ISS Governance QualityScore di Terns Pharmaceuticals, Inc. al 1 maggio 2024 è 8. I criteri di valutazione fondamentali sono revisione: 9; Consiglio di Amministrazione: 8; diritti degli azionisti: 8; retribuzione: 8.